Immuno-Oncology | Specialty

Five-Year Analysis Shows Ipilimumab More Than Doubles OS in Advanced Melanoma

February 27th 2015

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

PD-1 Inhibition Requires Further Refinement in Melanoma

February 25th 2015

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting

February 20th 2015

Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.

Dr. Brahmer on Immunotherapy Development in Lung Cancer

February 17th 2015

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.

FDA Schedules Advisory Meeting for T-VEC in Metastatic Melanoma

February 12th 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy talimogene laherparepvec as a treatment for patients with metastatic melanoma.

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12th 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

FDA Grants Reolysin Orphan Drug Designation for Ovarian Cancer

February 12th 2015

The FDA has granted an orphan drug designation to Reolysin for the treatment of patients with ovarian cancer.

FDA Grants Breakthrough Status to PD-L1 Inhibitor MPDL3280A in NSCLC

February 2nd 2015

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

Dr. Jeffrey Weber on Ipilimumab for Melanoma

February 2nd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.

Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma

January 29th 2015

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, talks about the toxicity of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

PD-1 Inhibition: The Changing Treatment Paradigm for Melanoma

January 29th 2015

An increased understanding of tumor immunology has led to seven new melanoma drug approvals since 2011, including the recent approvals of the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

Targeted Therapies and Immunotherapies Are Transforming Outcomes in Advanced NSCLC

January 28th 2015

Ten or 15 years ago, a diagnosis of advanced non– small cell lung cancer (NSCLC) led directly to a discussion of chemotherapy.

Brahmer Expects Rapid Approval for First PD-1 Inhibitor in Lung Cancer

January 25th 2015

Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.

Complexities of Translating PD-1/PD-L1 Agents to Clinical Practice Emerge

January 20th 2015

As varying immunotherapy options become available for different types of cancers, researchers will have to take the next steps in clinical studies and in practice before the growing excitement over emerging agents can truly be translated into beneficial new therapies for patients.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Latest News & Insight: January 15, 2015

January 15th 2015

Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer

January 15th 2015

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Dendreon Revenue Rises, Despite Restructuring

January 14th 2015

Increased utilization of the autologous cellular immunotherapy sipuleucel-T (Provenge) led to a $20.1 million improvement in total revenue in 2014 for the manufacturer Dendreon, when compared with 2013.

Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

January 13th 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Expert Discusses Integration of PD-1 Inhibitors Into Clinical Practice

January 13th 2015

To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.